It’s Better to Hope for Prosperity than Become Adversary: Arcturus Therapeutics Holdings Inc (ARCT) Stock
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
Hold on to your shares: Arcturus Therapeutics Holdings Inc (ARCT) Stock
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
Canaccord Genuity Assigned “a Buy” Rating to Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) Stock
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
Don’t be afraid of Arcturus Therapeutics Holdings Inc (ARCT) Stock despite uncertainty and doubt
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
Analyzing Arcturus Therapeutics Holdings Inc’s (ARCT) Stock earnings per share and revenue
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
